$4.2B deal: GSK and Merck KGaA to develop cancer immunotherapy
GlaxoSmithKline is teaming up with Merck KGaA of Germany in a multibillion-deal to jointly develop an experimental immunotherapy treatment for multiple difficult-to-treat cancers.…
GlaxoSmithKline is teaming up with Merck KGaA of Germany in a multibillion-deal to jointly develop an experimental immunotherapy treatment for multiple difficult-to-treat cancers.…